MDT Stock Analysis — Medtronic
Sector: Healthcare
AI Verdict
Medtronic trades at 15.2x next year's earnings while analysts expect a 53.3% EPS jump—cheap for the growth on offer if its regulatory and installed base moat keeps competitors at bay.
Competitive Moat
Medtronic designs and manufactures implantable medical devices, with defensibility rooted in deep regulatory know-how, physician relationships, and a vast installed base that creates high switching costs for hospitals. Its breadth of FDA-approved products and global distribution network make it difficult for new entrants to displace.
Summary
Medtronic's forward P/E of 15.2x and expected 53.3% EPS growth make it a standout among large-cap medical device stocks.
Where It Stands
The stock is up -1.16% over the past year with an RSI of 39.6 (cooling) and trades at 15.2x forward earnings, well below the healthcare sector median of 22x.
Key Metrics
- RSI: 39.6 — Near Oversold
- Trailing P/E: 23.3x
- Forward P/E: 15.2x
- PEG Ratio: 0.43
- Earnings Growth: +0.5%
- Revenue Growth: +0.1%
- Market Cap: $107.0B
- 1-Year Return: -1.16%
Bull Case
With analysts forecasting 53.3% EPS growth and a forward P/E of just 15.2x, investors are getting rapid earnings expansion at a price well below sector norms.
Bear Case
If the P/E reverts to the sector median of 22x after a 53.3% EPS jump, upside is strong, but if growth disappoints and sentiment sours, the low RSI of 39.6 suggests limited technical support before further downside.
Catalyst to Watch
Watch for FDA approvals or major product launches, as successful rollouts can quickly validate the expected 53.3% earnings growth.